Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
暂无分享，去创建一个
E. Topol | G. Stone | B. Meier | N. Lakkis | D. Cohen | D. Moliterno | D. Chew | C. Hamm | R. Lange | G. Jia | P. Dibattiste | I. Casserly